# Biological Sovereignty & Extraction

In research ethics, does the flow of biological samples from African trial participants to Northern laboratories constitute a pattern of biological extraction? This audit evaluated 23,873 African interventional trials on ClinicalTrials.gov for indicators of sample export including foreign biobank designation and Northern laboratory collaborator metadata through March 2026. Investigators reported the estimated sample-export rate as the primary estimand for biological sovereignty. An estimated seventy-eight percent of African trials involving biological sample collection designated analysis at non-African institutions, while only fifteen percent included local laboratory capacity building. Africa's 1,149 biomarker-driven trials represented less than five percent of the continental total compared to 8% in the United States. The biological extraction pipeline mirrors historical patterns of resource exploitation where raw materials flow northward and value-added products return southward at premium prices. These findings quantify the biological sovereignty deficit as a structural feature of the current research system. Interpretation is limited by the inference of sample-flow direction from collaborator metadata rather than direct tracking.

## References

1. de Vries J, et al. ""; returning"; individual research results in Africa." Nat Genet. 2012;44:370-374.
2. Benatar SR. "Reflections and recommendations on research ethics in developing countries." Soc Sci Med. 2002;54:1131-1141.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/health-disease/dashboards/biological-extraction.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/health-disease/code/biological-extraction.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05